Dear Community, We are happy to provide you with a new episode of our “DID YOU KNOW…” series – this time with a focus...
The FibreGum study – Changing the course of obesity
The FibreGum study – Changing the course of obesity
The goal of our study is to increase weight reduction in obese children and adolescents by stimulating the gut microbiome with a chewing-gum containing dietary fibres as an adjunct treatment to standard adiposity therapy.
Around one in six children in Switzerland is affected by overweight or obesity and the prevalence continues to rise. This increase in obesity and its associated comorbidities represents a huge socio-economic burden, as it leads to increased morbidity and mortality. Obesity is not only a chronic disease in itself, but also a major risk factor for the development of the world’s leading causes of poor health and early death; namely cardiovascular disease, various cancers, diabetes and osteoarthritis.
Read more about the project here.
More recent news
DCB Newsletter #3/26: DID YOU KNOW… why type 1 diabetes is rising and what projections to 2050 tell us?
DCB Newsletter #2/26: IT’S A WRAP! A Recap of The Insulin Insight Conference 2026
Dear Community, The Insulin Insight Conference 2026 recently took place at sitem-insel AG in Bern. It brought together...
DCB Newsletter #5/25: INSIDE DCB – Our Milestones in 2025
Dear DCB community, As we approach the end of this year, we want to take the opportunity to look back on our team’s...


